Nascent Biotech, Inc. (OTCPK: NBIO)
Health Care · Biotechnology · US
$0.00
-50.00% today · -66.7% 1Y
Nascent Biotech, Inc. (OTCPK: NBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $51.85K and employs 2 people.
Over the last twelve months the share price has lost 66.7%, trading between 0.00 and 0.13.
Tweenvest scores Nascent Biotech, Inc. across four factors: quality 38/100. Its strongest factor is quality.
NBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.85K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 1.88
- 52-week high
- $0.13
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 172.84M
- Employees
- 2
- Next earnings
- —
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
- ISIN
- US63108Q1013
- Listed since
- Dec 3, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.